Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.
Metformin use may protect against knee cartilage damage in obese people with knee osteoarthritis, suggests an analysis of Osteoarthritis Initiative participants.
The US FDA has approved a diagnostic test to aid detection of infections in the synovial fluid surrounding prosthetic joints in patients being considered for revision surgery.
A real-world study of patients with systemic lupus erythematosus suggests that those with more active disease and minimal previous immunosuppressive treatment are most likely to benefit from single-course treatment with rituximab.
US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.
Psoriatic arthritis patients with multiple comorbidities have worse physical function than those with just one comorbidity, according to a cross-sectional analysis of the CARMA study of patients from daily clinical practice in Spain.
Rheumatoid arthritis patients receiving Janus kinase inhibitors may not be at increased risk for cardiovascular events in the short term, suggests a meta-analysis of randomized controlled trials comparing the active agents with placebo.
Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.
Findings from the SENSCIS trial indicate that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated interstitial lung disease.
The clinical benefit of infliximab dose escalation in people with rheumatoid arthritis may be limited to the initial two escalations, US study findings indicate.
Patients initiating their first tumor necrosis factor inhibitor for psoriatic arthritis have a longer time to discontinuation and are less likely to switch treatment than those previously treated with a drug from the same class, say researchers.
Analysis of data from 21 randomized controlled trials indicates that the interleukin-17A inhibitor secukinumab has a favorable long-term safety profile among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis.
SMILE, an individualized and culturally tailored patient decision aid, has been shown to reduce decisional conflict regarding choice of immunosuppressive treatment in a randomized trial involving a diverse group of women with lupus nephritis.
Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.
Supervised low-load resistance training combined with partial blood flow restriction is as effective as high‐load resistance training in improving muscle strength and function in women with rheumatoid arthritis (RA), study findings indicate.
Approximately one in five people diagnosed with rheumatoid arthritis will need a knee or hip replacement during their remaining lifetime, shows an analysis of data from the UK’s National Health Service.
The authors of a systematic review and meta-analysis have identified several modifiable and nonmodifiable risk factors for falls following hip or knee replacement.
The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.
Findings from a systematic review and meta-analysis indicate that the incidence of herpes zoster among rheumatoid arthritis patients treated with Janus kinase inhibitors is higher than expected in this population, and baricitinib is associated with a significantly increased risk.